Abstract: Antiangiogenic targeted therapy plays an important role in the treatment of malignant tumors, especially in the process of antitumor treatment including transformation stage, late stage, and maintenance stage. Apatinib (YN968D1) is a self-developed antiangiogenic targeted agent that was approved and launched for third-line and subsequent-line treatment for advanced gastric adenocarcinoma or gastro-esophageal junction adenocarcinoma. Moreover, the use of apatinib for other multiple solid tumors has been investigated. With an increase in the number of clinical studies on apatinib, concerns have been raised about its safety. Hence, we highlight the common adverse reactions of apatinib in clinical application and the incidences of various adverse events in different tumor treatments. We provide a comprehensive analysis of available clinical data and compare the advantages and disadvantages of apatinib with other common antiangiogenic drugs regarding their adverse reactions. Overall, these results will help to provide a better understanding of the safety of this medicine in the hope of helping physicians to provide patients with a safe and effective treatment.